Aquestive Therapeutics (AQST) Operating Expenses (2017 - 2026)

Aquestive Therapeutics' Operating Expenses history runs 10 years deep, the most recent figure standing at $18.6 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 33.59% year-over-year to $18.6 million; the TTM figure through Mar 2026 stood at $106.2 million (up 11.27% YoY), while the FY2025 annual figure was $115.6 million, up 30.87% from the prior year.
• Operating Expenses was $18.6 million for Q1 2026 at Aquestive Therapeutics, down from $41.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $41.9 million in Q4 2025 to a low of $15.4 million in Q3 2023.
• Historically, Operating Expenses has averaged $22.2 million across 5 years, with a median of $21.4 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses soared 64.48% in 2025, then tumbled 33.59% in 2026.
• A 5-year view of Operating Expenses shows it stood at $21.4 million in 2022, then decreased by 20.0% to $17.1 million in 2023, then surged by 48.66% to $25.4 million in 2024, then jumped by 64.48% to $41.9 million in 2025, then sank by 55.44% to $18.6 million in 2026.
• The last three Operating Expenses figures came in at $18.6 million (Q1 2026), $41.9 million (Q4 2025), and $24.3 million (Q3 2025), per Business Quant data.